SCHEMBL981923

SCHEMBL981923

O=C(Cc1ccc(F)cc1)N1CCC(c2ccco2)=N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40
ATM Q13315 1/20 0.40
MAPT P10636 1/20 0.39
ALDH1A1 P00352 3/20 0.39
USP2 O75604 1/20 0.39
KDM4E B2RXH2 1/20 0.38
RAB9A P51151 1/20 0.38
NCOA1 Q15788 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17004389 0.89 ALDH1A1 (0.50) POLBL3MBTL1SMN1; SMN2TDP1CYP2C9
SCHEMBL979978 0.85 ALDH1A1 (0.55) L3MBTL1SMN1; SMN2CYP2C9CYP2C19CYP1A2
SCHEMBL980870 0.81 MAOB (0.53) POLBSMN1; SMN2MAOBHPGDMAPT
SCHEMBL982164 0.79 KDM4E (0.48) POLBL3MBTL1SMN1; SMN2TDP1HPGD
SCHEMBL981914 0.78 POLB (0.42) POLBSMN1; SMN2TDP1MAPTALDH1A1
SCHEMBL980368 0.78 SIGMAR1 (0.47) POLBL3MBTL1SMN1; SMN2TDP1MAOB
SCHEMBL12922889 0.78 MAOB (0.50) POLBL3MBTL1SMN1; SMN2MAOBHPGD
SCHEMBL981737 0.77 ME2 (0.51) POLBSMN1; SMN2MAOBHPGDMAPT
SCHEMBL982401 0.76 ALDH1A1 (0.46) POLBL3MBTL1SMN1; SMN2TDP1HPGD
SCHEMBL981953 0.76 MEN1 (0.52) POLBL3MBTL1SMN1; SMN2MAOBCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 POLB 3230/4885L3MBTL1 336/4885SMN1; SMN2 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.